La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264
Debt
Debt-to-Equity RatioN/A
Current Ratio10.09
Quick Ratio10.04
Price-To-Earnings
Trailing P/E Ratio-5.63
Forward P/E Ratio-4.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$620,000.00
Price / Sales1,285.15
Cash FlowN/A
Price / CashN/A
Book Value$3.68 per share
Price / Book8.28
Profitability
EPS (Most Recent Fiscal Year)($5.41)
Net Income$-114,800,000.00
Net MarginsN/A
Return on Equity-118.62%
Return on Assets-97.15%
Miscellaneous
Employees309
Outstanding Shares26,150,000
La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions
What is La Jolla Pharmaceutical's stock symbol?
La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical's earnings last quarter?
La Jolla Pharmaceutical (NASDAQ:LJPC) issued its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($2.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.48) by $0.74. The biopharmaceutical company had revenue of $0.81 million for the quarter. View La Jolla Pharmaceutical's Earnings History.
When is La Jolla Pharmaceutical's next earnings date?
What price target have analysts set for LJPC?
6 brokers have issued 1 year price objectives for La Jolla Pharmaceutical's shares. Their predictions range from $20.00 to $115.00. On average, they expect La Jolla Pharmaceutical's share price to reach $61.1667 in the next year. View Analyst Ratings for La Jolla Pharmaceutical.
What are Wall Street analysts saying about La Jolla Pharmaceutical stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
- 1. Chardan Capital analysts commented, "We note that Protagonist Therapeutics (unrated) has also presented data on its hepcidin mimetic, PTG-300, a potential competitor of LJPC-401. Protagonist’s EHA abstract indicated that PTG-300 in healthy volunteers leads to longer suppression of iron levels when compared to LJPC-401. We note that LJPC-401 is naturally-occurring while PTG-300 is a mimetic to the natural peptide (see S-1), which could potentially lead to antibodies against the unnatural PTG-300. La Jolla reported analysis of samples from its clinical trials has not shown antibodies to LJPC-401. The data shown Please refer to important disclosure information and Regulation Analyst Certification found on pages 14 – 16 of this report.by Protagonist seem to also indicate a potential plateauing effect at the 20 mg dose, akin to what was seen in the La Jolla study." (6/18/2018)
- 2. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (5/17/2018)
- 3. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) 660.6 Market Cap (M) $815 Public Market Float (M) 6.0 Shares Outstanding (M) 26.2 3 Interest (M) 7.32 Cash (M) $154.4 Total Debt (M) $0.0 Quarterly EPS may not sum to total due to rounding or change in share count." (5/11/2018)
Who are some of La Jolla Pharmaceutical's key competitors?
Some companies that are related to La Jolla Pharmaceutical include Crispr Therapeutics (CRSP), argenx (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Atara Biotherapeutics (ATRA), Repligen (RGEN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Acorda Therapeutics (ACOR) and Cellectis (CLLS).
Who are La Jolla Pharmaceutical's key executives?
La Jolla Pharmaceutical's management team includes the folowing people:
- Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 58)
- Mr. Dennis M. Mulroy, CFO & Principal Accounting Officer (Age 63)
- Ms. Jennifer A. Carver MBA, Chief Operating Officer (Age 64)
- Dr. Lakhmir S. Chawla M.D., Chief Medical Officer (Age 47)
- Mr. James M. Rolke, Chief Scientific Officer (Age 49)
Has La Jolla Pharmaceutical been receiving favorable news coverage?
Headlines about LJPC stock have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. La Jolla Pharmaceutical earned a news impact score of 0.24 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are La Jolla Pharmaceutical's major shareholders?
La Jolla Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (15.83%), BLACKROCK INC. (4.60%), BlackRock Inc. (4.46%), Scopia Capital Management LP (2.21%), Candriam Luxembourg S.C.A. (1.33%) and Artal Group S.A. (1.15%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.
Which institutional investors are selling La Jolla Pharmaceutical stock?
Which institutional investors are buying La Jolla Pharmaceutical stock?
LJPC stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Scopia Capital Management LP, Artal Group S.A., Rock Springs Capital Management LP, UBS Group AG, Candriam Luxembourg S.C.A., Asymmetry Capital Management L.P. and Cowen Inc.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.
How do I buy shares of La Jolla Pharmaceutical?
Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical's stock price today?
One share of LJPC stock can currently be purchased for approximately $30.47.
How big of a company is La Jolla Pharmaceutical?
La Jolla Pharmaceutical has a market capitalization of $805.56 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-114,800,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. La Jolla Pharmaceutical employs 309 workers across the globe.
How can I contact La Jolla Pharmaceutical?
La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]
MarketBeat Community Rating for La Jolla Pharmaceutical (LJPC)
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
